Kuwait vs Slovenia: HIV/AIDS deaths averted by antiretroviral therapy
Kuwait
27 deaths
in 2022
Slovenia
36.62 deaths
in 2024
Kuwait rank
144th
Slovenia rank
141st
HIV/AIDS deaths averted by antiretroviral therapy over time
- Kuwait
- Slovenia
How they compare
Slovenia currently reports 36.62 deaths against 27 deaths in Kuwait, a difference of 9.62 deaths.
That makes Slovenia's figure about 1.4 times Kuwait's.
The two have swapped places 2 times across 33 shared years of data; in 1990 it was Slovenia ahead.
Kuwait ranks 144th and Slovenia ranks 141st of 157 countries.
Across the 4 decades both report, Kuwait averaged higher in 1 and Slovenia in 3.
Head to head by decade
| Decade | Kuwait | Slovenia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 1.5 deaths | 0.7306 deaths | 0.7694 deaths | Kuwait |
| 2000s | 6.3 deaths | 10.07 deaths | 3.77 deaths | Slovenia |
| 2010s | 15.7 deaths | 22.1 deaths | 6.4 deaths | Slovenia |
| 2020s | 25.33 deaths | 33.44 deaths | 8.11 deaths | Slovenia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Kuwait or Slovenia?
- Slovenia, at 36.62 deaths against 27 deaths in Kuwait as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Kuwait and Slovenia?
- 9.62 deaths, with Slovenia ahead.
- How many years of comparable data are there for Kuwait and Slovenia?
- 33 years are reported by both, from 1990 to 2022.
- How do Kuwait and Slovenia rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Kuwait ranks 144th and Slovenia ranks 141st of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.